In the aftermath of Hurricane Harvey and Hurricane Irma, the Cystic Fibrosis Foundation has provided the following resources. Our Compass team continues to stand by and offer support of those impacted by these storms.
In the aftermath of Hurricane Harvey, our hearts go out to the many people impacted by the storm and flooding, particularly those in our cystic fibrosis community.
The U.S. Food and Drug Administration (FDA) approved the use of ivacaftor (Kalydeco®) today for people ages 2 and older with cystic fibrosis who have at least one of the following five splice mutations: 3849+10kbC->T, 2789+5G->A, 3272-26A->G, 711+3A->G, E831X.
New data show positive results in individuals with a single F508del mutation as well as people with two copies of F508del and support continued development of triple combination therapies.
As part of the Cystic Fibrosis Foundation's ninth annual Teen Advocacy Day, 162 advocates from 38 states met with elected officials in Washington, D.C., to tell their stories and make sure the cystic fibrosis community is heard in ongoing health care reform discussions.
Today, the U.S. Senate released its version of the health care reform bill, titled the Better Care Reconciliation Act, and in response, the Cystic Fibrosis Foundation affirmed its opposition to the legislation.
The Cystic Fibrosis Foundation today mourns the passing of legendary sports journalist Frank Deford, whose young daughter Alex lost her fight to CF in 1980, and who served as chair of the Cystic Fibrosis Foundation's Board of Trustees from 1982-1999.
The U.S. Food and Drug Administration (FDA) today approved ivacaftor (Kalydeco®) for people ages 2 and older who have at least one of 23 residual function mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.
The U.S. House of Representatives has passed the American Health Care Act (AHCA), legislation that fails to adequately protect people living with cystic fibrosis.
Watch the entire leadership conference, including all of the break-out sessions and Medical Hot Topics, from start to finish.